Abstract
Purpose: The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are important new agents in the care of patients with hormone receptor-positive (HR+) and HER2-negative (HER2–) advanced breast cancer. CDK4/6 inhibitors are generally well tolerated, although neutropenia is a significant class-wide adverse effect. Frequent monitoring of the full blood count (FBC) is required during treatment so that neutropenia is managed with appropriate dose interruption and/or dose reduction. We sought to assess the impact of repeated visits to the oncology outpatient clinic as well as waiting time for FBC results.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
